A developer of a drug designed to treat a variety of food allergies raised $119 million as it prepares for a potentially pivotal clinical trial.
Alladapt Immunotherapeutics Inc. announced the new funding deal Wednesday. Patient Square Capital's Enavate Sciences unit led the round. Founding investor Gurnet Point Capital and new investors AllerFund, Novartis AG, Red Tree Venture Capital and WestRiver Group participated in the deal.
The Menlo Park company had previously raised a total of $63 million…
